Switch theme
Sign up to access all valuation multiples
Bioton SA is a Poland based company engaged in the principal business activity of manufacturing medicines and pharmaceutical preparations and production of pharmaceutical substances. The products of the company include recombinant human insulin in pharmaceutical substance form and as preparations for injections; glimepiride, an oral hypoglycemic drug; and metformin, an oral hypoglycemic drug. Its products line focuses on diet supplements, products for particular nutritional uses and cosmetics dedicated to patients with certain health problems. The group operates in Poland and internationally, of which majority of the revenue is derived from Poland.
1989
579
LTM Revenue $57.5M
LTM EBITDA $9.3M
$108M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Bioton has a last 12-month revenue (LTM) of $57.5M and a last 12-month EBITDA of $9.3M.
In the most recent fiscal year, Bioton achieved revenue of $55.1M and an EBITDA of $8.6M.
Bioton expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Bioton valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $57.5M | XXX | $55.1M | XXX | XXX | XXX |
| Gross Profit | $47.9M | XXX | $17.2M | XXX | XXX | XXX |
| Gross Margin | 83% | XXX | 31% | XXX | XXX | XXX |
| EBITDA | $9.3M | XXX | $8.6M | XXX | XXX | XXX |
| EBITDA Margin | 16% | XXX | 16% | XXX | XXX | XXX |
| EBIT | -$0.2M | XXX | -$1.5M | XXX | XXX | XXX |
| EBIT Margin | 0% | XXX | -3% | XXX | XXX | XXX |
| Net Profit | -$2.3M | XXX | -$4.2M | XXX | XXX | XXX |
| Net Margin | -4% | XXX | -8% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $8.0M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Bioton's stock price is PLN 4 (or $1).
Bioton has current market cap of PLN 361M (or $95.6M), and EV of PLN 408M (or $108M).
See Bioton trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $108M | $95.6M | XXX | XXX | XXX | XXX | $-0.03 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Bioton has market cap of $95.6M and EV of $108M.
Bioton's trades at 2.0x EV/Revenue multiple, and 12.5x EV/EBITDA.
Equity research analysts estimate Bioton's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Bioton has a P/E ratio of -41.2x.
See valuation multiples for Bioton and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $95.6M | XXX | $95.6M | XXX | XXX | XXX |
| EV (current) | $108M | XXX | $108M | XXX | XXX | XXX |
| EV/Revenue | 1.9x | XXX | 2.0x | XXX | XXX | XXX |
| EV/EBITDA | 11.6x | XXX | 12.5x | XXX | XXX | XXX |
| EV/EBIT | -432.6x | XXX | -71.4x | XXX | XXX | XXX |
| EV/Gross Profit | 2.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | -41.2x | XXX | -23.0x | XXX | XXX | XXX |
| EV/FCF | 16.6x | XXX | 16.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBioton's last 12 month revenue growth is 10%
Bioton's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $32K for the same period.
Bioton's rule of 40 is 38% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Bioton's rule of X is 41% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Bioton and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Margin | 16% | XXX | 16% | XXX | XXX | XXX |
| EBITDA Growth | 33% | XXX | -9% | XXX | XXX | XXX |
| Rule of 40 | 38% | XXX | 26% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 41% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $32K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 17% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 34% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Bioton acquired XXX companies to date.
Last acquisition by Bioton was XXXXXXXX, XXXXX XXXXX XXXXXX . Bioton acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Bioton founded? | Bioton was founded in 1989. |
| Where is Bioton headquartered? | Bioton is headquartered in Poland. |
| How many employees does Bioton have? | As of today, Bioton has 579 employees. |
| Is Bioton publicy listed? | Yes, Bioton is a public company listed on WAR. |
| What is the stock symbol of Bioton? | Bioton trades under BIO ticker. |
| When did Bioton go public? | Bioton went public in 2005. |
| Who are competitors of Bioton? | Similar companies to Bioton include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Bioton? | Bioton's current market cap is $95.6M |
| What is the current revenue of Bioton? | Bioton's last 12 months revenue is $57.5M. |
| What is the current revenue growth of Bioton? | Bioton revenue growth (NTM/LTM) is 10%. |
| What is the current EV/Revenue multiple of Bioton? | Current revenue multiple of Bioton is 1.9x. |
| Is Bioton profitable? | Yes, Bioton is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Bioton? | Bioton's last 12 months EBITDA is $9.3M. |
| What is Bioton's EBITDA margin? | Bioton's last 12 months EBITDA margin is 16%. |
| What is the current EV/EBITDA multiple of Bioton? | Current EBITDA multiple of Bioton is 11.6x. |
| What is the current FCF of Bioton? | Bioton's last 12 months FCF is $6.5M. |
| What is Bioton's FCF margin? | Bioton's last 12 months FCF margin is 11%. |
| What is the current EV/FCF multiple of Bioton? | Current FCF multiple of Bioton is 16.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
